HEALTHSCMP WORLD
Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
Akeso's lung cancer drug ivonescimab showed better-than-expected clinical results for treating a type of lung cancer common in smokers. Analysts believe it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and raised target prices. Phase three trials found the drug reduced the risk of death.
Related Signal
Adjacent reporting
- Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
- STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
- Chinese drug reduces lung cancer death risk by 34% in trial
- A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
- STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows
- Drugs that boost immunity are making lung cancer less deadly